Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 384

Key Protein Regulates DNA Enzymes, Supporting Genome Stability

Summary: Researchers have discovered that the protein USP50 regulates DNA replication by managing which enzymes—nucleases or helicases—cleave or unwind DNA strands during replication. This control is crucial for stable replication, especially when the process encounters issues that need restarting. When USP50 is absent, cells struggle to coordinate enzyme use, leading to replication errors and potential genetic instability.

The findings provide new insights into genome maintenance and may help explain some hereditary conditions, such as early-onset aging and certain cancers. Understanding USP50’s role opens doors to potential therapeutic strategies aimed at protecting DNA integrity.

“The New Chemotherapy”: Duo Oncology Introduces First Innovative Cancer-Fighting Nanomedicine in Over a Decade

Fortunately, the past decade has experienced a boom, with over 200 startups bringing novel cancer therapies—primarily antibodies, viruses, or cells—into clinical trials aiming to find alternatives to toxic chemotherapy. Despite these innovations, chemotherapy remains an essential yet toxic part of cancer care. In Pittsburgh, a small team of scientist-entrepreneurs and oncologists started meeting every Friday morning before work, collaborating to search for a new chemistry, one that could replace toxic chemotherapies. Their search soon focused on compelling research about novel ultra-small nanomedicine chemistry that carried potent drugs deep into solid tumors while sparing healthy organs.

This new nanomedicine chemistry fascinated Dr. Sam Rothstein, a scientist-entrepreneur with 20+ years of nanomedicine research experience spanning academia and industry. “We could make a real positive impact on patients,” says Rothstein. “We know that nanomedicines, which keep potent therapies out of healthy organs, improve quality of life. But this novel ultrasmall chemistry could go even further, saving lives by reaching remote cancer cells that current therapies can’t touch.”

Dr. Rothstein set to work building a new company, calling on connections made over a 10+-year career as a life science startup CEO and CSO, where he founded and grew two nanomedicine startups from academic discoveries. After months of market, regulatory, and business research, Duo Oncology was born.

Tech Millionaire Bryan Johnson Claims His “Super Plasma” Reversed His Father’s Age By 25 Years

Bryan Johnson, a millionaire tech entrepreneur dedicated to reversing ageing, recently took to social media to boast about his “super clean plasma.” In a detailed post on X, he shared that a lab technician couldn’t bring himself to dispose of the plasma after a total plasma exchange (TPE) procedure.

Johnson claims to have reduced his epigenetic age through his comprehensive regimen called Project Blueprint. He follows a strict diet and exercise routine, spends over $2 million annually on a team of doctors and medical equipment, and undergoes both experimental and conventional treatments-including the recent TPE procedure.

TPE, a procedure often used in regenerative medicine and anti-ageing treatments, involves replacing a patient’s plasma with donor plasma or a substitute fluid. In Johnson’s case, his plasma was replaced with albumin.

Making micelles more effective for dye and drug dispersion through well-defined core-shell structures

Micelles are spherical molecular structures usually formed by amphiphilic molecules with block structure, which contain both hydrophilic and hydrophobic parts. The hydrophobic tails of these molecules cluster together to form a core, while the hydrophilic heads face outward, creating a protective shell. This structure allows micelles to encapsulate hydrophobic substances within their core and disperse them in a water-based environment.

Stem cell capsules restore motor function in Parkinson’s rats

Neural microtissues derived from pluripotent stem cells (iPSCs) can replace dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, and restore motor function when grown into tiny capsules and transplanted into the brains of model rats, a study led by TreeFrog Therapeutics found.

“TreeFrog Therapeutics has overcome the most complex challenges of developing a successful treatment for Parkinson’s disease using our C-Stem platform technology and producing a therapy containing mature dopaminergic neurons with a unique 3D format that promotes cell survival post-graft with proven pre-clinical results,” Jens Schroeder, MD, PhD, TreeFrog’s chief medical officer, said in a company press release.

The study, “Bioreactor-produced iPSCs-derived dopaminergic neuron-containing neural microtissues innervate and normalize rotational bias in a dose-dependent manner in a Parkinson rat model,” was published in Neurotherapeutics.